Inverse relationship between peroxisomal and mitochondrial beta-oxidation in HepG2 cells treated with dehydroepiandrosterone and clofibric acid.
A transformed human hepatoma cell line was examined to determine if it was an appropriate model system for studying the mechanism of action of two peroxisome proliferators that lower blood lipids. Cultures of HepG2 cells were exposed to four different concentrations of either the hypolipidemic drug, clofibric acid (CLO), or the adrenal steroid, dehydroepiandrosterone (DHEA). Activities of two peroxisomal enzymes, palmitoyl-CoA oxidase and catalase, and two mitochondrial enzymes, carnitine palmitoyl-CoA transferase and succinate-INT-reductase, were measured in CLO- and DHEA-treated cells. In general, as the concentration of these hypolipidemic agents increased from 0 to 1000 microM, the specific activities of peroxisomal palmitoyl-CoA oxidase and catalase increased, and mitochondrial carnitine palmitoyl-CoA transferase and succinate-INT-reductase decreased. The activity of lactate dehydrogenase was significantly higher in the medium of cultures exposed to the 500 and 1000 microM concentration of DHEA compared with the control cultures, indicating the cytotoxic effects of this steroid at millimolar levels in vitro. In summary, the peroxisomal proliferators, DHEA and CLO, inversely altered peroxisomal and mitochondrial beta-oxidation in HepG2 cultures, but not to the extent reported for rat hepatocytes in vitro. In vitro concentrations of DHEA greater than 500 microM adversely affected the viability of HepG2 cells. The results of this study suggest that beta-oxidation in this human hepatoma cell line may not be as sensitive to hypolipidemic agents as are primary cultures of rat hepatocytes.
Chance
D S
DS
Department of Food, Nutrition, and Food Service Management, University of North Carolina at Greensboro 27412.
Wu
S M
SM
McIntosh
M K
MK
D000704:Analysis of Variance; D015415:Biomarkers; D006528:Carcinoma, Hepatocellular; D002334:Carnitine O-Palmitoyltransferase / Q000378:metabolism; D002374:Catalase / Q000378:metabolism; D002460:Cell Line; D002461:Cell Line, Transformed; D002994:Clofibrate / Q000494:pharmacology*; D003687:Dehydroepiandrosterone / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007700:Kinetics; D008113:Liver Neoplasms; D008830:Microbodies / Q000187:drug effects / Q000201:enzymology*; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology*; D010084:Oxidation-Reduction; D010088:Oxidoreductases / Q000378:metabolism; D013384:Succinate Cytochrome c Oxidoreductase / Q000378:metabolism; D014407:Tumor Cells, Cultured
D015415:Biomarkers; D003687:Dehydroepiandrosterone; D010088:Oxidoreductases; D013384:Succinate Cytochrome c Oxidoreductase; D002374:Catalase; C028427:palmitoyl CoA oxidase; D002334:Carnitine O-Palmitoyltransferase; D002994:Clofibrate